Investigation Report on China Telmisartan Market, 2009-2018
- Geography Covered
According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.
Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name "Micardis". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as "Micardis" by Boehringer Ingelheim and "Pritor" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004.
Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to CRI, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market.
The CAGR of sales value of telmisartan surpassed 65% in Chinese sample hospitals from 2005 to 2010. Its growth rate dropped slightly in 2011, but an annual growth rate of 10% is still maintained. From the perspective of sales revenue, original drug produced by Boehringer Ingelheim has seized most of Chinese telmisartan market while other market share is occupied by generic drugs produced by manufacturers such as Yichang Changjiang Pharmaceutical Co., Ltd. and Beijing Double-Crane Pharmaceutical Co., Ltd. It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard, changes of eating habit, increasing stress of life and lack of health awareness. As Chinese people's incomes increase, the affordability of antihypertension drugs increases. Estimation shows that market size of telmisartan in China will keep rising in the next few years.
Through this report, the readers can acquire the following information:
-Market Share of Telmisartan Produced by Different Manufacturers in China Hospital Market
-Sales price of Telmisartan in China Hospital Market
-Major Telmisartan Manufacturers in China
-Share of Telmisartan in Different Dosage Forms in China Hospital Market
-Prospect of China Telmisartan Market
The following enterprises and people are recommended to purchase this report:
-Antihypertensive APIs and Finished Product Manufacturers
Table of Contents
1 Relevant Concepts of Telmisartan
1.2 Sales Status on the Global Market
2 Market Overview of Telmisartan in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 Investigation on Sales Value of Telmisartan in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 Investigation on Market Share of Major Telmisartan Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Investigation on Market Size of Telmisartan by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 Reference Price of Telmisartan Produced by Different Enterprises in China Hospital Market
6.1 Boehringer Ingelheim
6.2 Yichang Changjiang Pharmaceutical Co., Ltd.
6.3 Beijing Double-Crane Pharmaceutical Co., Ltd.
6.4 Hainan Selection Pharmaceutical Co., Ltd.
6.5 Wanbang Biopharmaceutical Co., Ltd.
6.6 Beijing SL Pharmaceutical Co., Ltd.
6.7 Dawnrays Pharmaceutical (Holdings) Limited
7 Analysis on Major Telmisartan Manufacturers in China, 2009-2013
7.1 Boehringer Ingelheim
7.2 Yichang Changjiang Pharmaceutical Co., Ltd.
7.3 Beijing Double-Crane Pharmaceutical Co., Ltd.
7.4 Hainan Selection Pharmaceutical Co., Ltd.
7.5 Wanbang Biopharmaceutical Co., Ltd.
8 Prospect of China Telmisartan Market, 2014-2018
8.1 Trend of Hypertension Incidence in China
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern
Chart Telmisartan Products Approved to Market in China by 2014
Chart Sales Value of Telmisartan in Global Market, 2009-2013
Chart Sales Value of Telmisartan in China Hospital Market, 2009-2013
Chart Sales Value of Telmisartan by Region in China, 2009-2013
Chart Market Share of Telmisartan Enterprises by Sales Value in China, 2009-2013
Chart Price of Telmisartan Produced by Boehringer Ingelheim in China Hospital Market, 2014
Chart Price of Telmisartan Produced by Yichang Changjiang Pharmaceutical Co., Ltd. in China Hospital Market, 2014
Chart Forecast on Market Size of Hospital-use Telmisartan in China, 2014-2018